ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Lancet · 2026-10-24

In 970 patients with refractory metastatic colorectal cancer in Japan, a 14-day trifluridine-tipiracil plus bevacizumab schedule was non-inferior to the 28-day schedule for overall survival (median 11·3 vs 10·3 months; HR 0·93), with less grade ≥3 neutropenia (13% vs 39%).

RCTn = 970
Sakakida et al. 14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan
Gastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25

In 342 patients with untreated unresectable hepatocellular carcinoma, adding atezolizumab plus bevacizumab to on-demand TACE lengthened median TACE-PFS (11.3 vs 7.0 months; HR 0.71). Overall survival, immature at interim analysis, showed no difference (HR 0.96).

RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Oncology · Lancet · 2026-08-22

In 201 patients with HCC and macrovascular invasion stable or responding on atezolizumab-bevacizumab, resection lengthened median time to treatment failure vs maintenance (20·4 vs 11·8 months; HR 0·60); grade 3–4 treatment-related events 39% vs 21%, 2 treatment-related deaths.

RCTn = 201
Sun et al. Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.